Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › IL › Winfield › NPI 1003864810
Hospital

Central Dupage Hospital Association

Central Dupage Hospital Association was paid $10.62M by Medicaid between Jan 2018 and Dec 2024, across 302 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 43% of everything it billed.

33Billing provider infoCENTRAL DUPAGE HOSPITAL ASSOCIATION
WINFIELD, IL 60190
33aNPI1003864810assigned 05/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.62M
24GClaims954,691
24DCodes billed302
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Illinois

Rank by total paid#1 of 129
Median peer was paid$547K
This provider vs. median19×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$250K$500K$750K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018313,222$3.18M
2019424,996$4.72M
2020182,540$2.13M
20213,976$17K
20225,752$133K
202310,194$185K
2024incomplete14,011$255K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 43% 50,973 10,288 $4.61M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 4.0% 27,677 23,651 $424K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 4.0% 27,729 23,694 $421K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 3.2% 15,237 13,243 $339K
97161 3.0% 4,352 2,802 $319K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 2.9% 2,145 1,735 $313K
84443 Thyroid stimulating hormone (TSH) 2.5% 43,332 38,335 $271K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder 2.2% 9,257 2,228 $235K
80053 Comprehensive metabolic panel 1.9% 63,588 55,099 $199K
87799 1.8% 5,323 3,165 $189K
87481 1.2% 6,313 3,841 $131K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1.1% 74,637 64,044 $112K
290 more codes
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 1.0% 2,886 $110K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.0% 9,052 $108K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,425 $105K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 17,500 $103K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 3,803 $99K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 9,793 $98K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 411 $93K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 29,262 $83K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 3,580 $83K
86480 <1% 3,575 $82K
81513 <1% 911 $77K
97162 <1% 1,098 $75K
77067 Screening mammography, bilateral, including computer-aided detection <1% 1,319 $74K
87086 Culture, bacterial; quantitative colony count, urine <1% 20,700 $69K
80061 Lipid panel <1% 36,653 $58K
87631 <1% 1,115 $55K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 2,856 $49K
86803 <1% 8,306 $48K
36415 Collection of venous blood by venipuncture <1% 40,938 $46K
83036 Hemoglobin; glycosylated (A1C) <1% 27,807 $44K
86769 <1% 1,084 $41K
87536 <1% 1,045 $39K
83655 <1% 7,531 $39K
81511 <1% 863 $38K
87510 <1% 5,017 $38K
87480 <1% 5,022 $37K
87512 <1% 3,909 $33K
84439 <1% 15,799 $32K
86235 <1% 1,981 $32K
71046 Radiologic examination, chest; 2 views <1% 2,702 $31K
82607 <1% 9,189 $31K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 1,114 $30K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 1,022 $30K
87081 <1% 14,128 $29K
83970 <1% 2,026 $28K
86003 <1% 13,218 $28K
84403 <1% 2,628 $27K
87522 Neg quan hep c or qual rna <1% 1,041 $27K
87660 <1% 4,994 $26K
94010 <1% 797 $23K
86038 <1% 4,138 $21K
87581 <1% 2,154 $21K
87486 <1% 2,143 $20K
80081 <1% 658 $20K
80048 Basic metabolic panel (calcium, ionized) <1% 6,015 $19K
87186 <1% 4,689 $17K
81001 <1% 23,910 $17K
97165 <1% 1,345 $16K
87340 <1% 6,951 $16K
84481 <1% 5,927 $15K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 1,019 $15K
83001 <1% 2,460 $14K
86696 <1% 1,665 $14K
80074 <1% 1,209 $14K
86146 <1% 560 $13K
86592 <1% 15,843 $13K
86787 <1% 2,490 $12K
82746 <1% 4,363 $12K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 696 $12K
83516 <1% 2,511 $12K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 2,885 $12K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 1,274 $12K
87077 <1% 4,775 $11K
84466 <1% 4,884 $11K
87070 <1% 5,051 $11K
82728 <1% 5,352 $10K
87088 <1% 2,921 $10K
85027 <1% 6,841 $10K
84702 <1% 3,572 $9K
84153 <1% 2,200 $9K
84402 <1% 1,858 $9K
86695 <1% 1,612 $8K
82784 <1% 1,758 $8K
86140 <1% 6,668 $8K
82105 <1% 1,362 $8K
82570 <1% 6,582 $8K
87511 <1% 541 $8K
77063 Screening digital breast tomosynthesis, bilateral <1% 712 $8K
86850 <1% 6,522 $8K
84146 <1% 2,029 $8K
83540 <1% 5,272 $7K
83735 <1% 4,453 $7K
82951 <1% 1,294 $7K
99213 Doctor's office visit, returning patient (routine) <1% 249 $7K
86431 <1% 3,228 $7K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 209 $6K
86800 <1% 1,906 $6K
86160 <1% 1,224 $6K
73610 <1% 357 $6K
86200 <1% 2,033 $6K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 346 $6K
86762 <1% 4,813 $6K
86665 <1% 461 $6K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 863 $6K
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel <1% 286 $6K
83520 <1% 1,054 $6K
82950 <1% 4,844 $6K
86376 <1% 2,329 $6K
85652 <1% 8,203 $6K
86706 <1% 1,380 $5K
86901 <1% 6,283 $5K
82043 <1% 5,502 $5K
86147 <1% 694 $5K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 632 $5K
83525 <1% 1,931 $5K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 194 $5K
73630 <1% 410 $5K
86225 <1% 1,430 $5K
82785 <1% 2,037 $5K
82670 <1% 1,700 $4K
86780 <1% 735 $4K
90686 <1% 244 $4K
88184 <1% 288 $4K
84550 <1% 3,581 $4K
92610 <1% 229 $4K
80076 <1% 1,587 $4K
82550 <1% 2,385 $4K
85610 <1% 3,302 $4K
86008 <1% 89 $4K
84480 <1% 1,115 $4K
86900 <1% 6,120 $4K
87209 <1% 659 $4K
83002 <1% 1,789 $4K
84144 <1% 1,309 $4K
86141 <1% 559 $3K
87338 <1% 377 $3K
83013 <1% 923 $3K
83021 <1% 906 $3K
80069 <1% 1,456 $3K
86304 <1% 306 $3K
87205 <1% 3,014 $3K
84305 <1% 737 $3K
86704 <1% 691 $3K
84460 <1% 1,744 $3K
73110 <1% 225 $3K
87045 <1% 733 $3K
86361 <1% 885 $2K
84100 <1% 2,141 $2K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 18 $2K
88142 <1% 1,124 $2K
84450 <1% 1,614 $2K
82533 <1% 639 $2K
99214 Doctor's office visit, returning patient (more involved) <1% 53 $2K
86039 <1% 772 $2K
86359 <1% 918 $2K
92523 <1% 92 $2K
83690 <1% 1,153 $2K
84681 <1% 523 $2K
88341 <1% 36 $2K
94664 <1% 128 $2K
74018 <1% 175 $2K
86735 <1% 608 $2K
88304 <1% 87 $2K
84156 <1% 3,004 $2K
85730 <1% 1,210 $2K
73560 <1% 143 $2K
82542 <1% 305 $2K
88342 <1% 431 $2K
97166 <1% 60 $2K
82947 <1% 1,699 $2K
86765 <1% 868 $1K
73130 <1% 159 $1K
82627 <1% 856 $1K
80197 <1% 331 $1K
81374 <1% 88 $1K
84163 <1% 404 $1K
84703 <1% 617 $1K
85007 <1% 1,540 $1K
86334 <1% 104 $1K
87177 <1% 646 $1K
83704 <1% 131 $1K
83880 <1% 207 $1K
72082 <1% 47 $1K
84165 <1% 457 $1K
83615 <1% 848 $1K
84436 <1% 842 $1K
87075 <1% 192 $1K
36416 <1% 500 $993.72
86060 <1% 383 $966.09
82150 <1% 637 $955.02
87563 <1% 120 $914.29
73140 <1% 168 $910.79
96040 <1% 14 $882.81
83090 <1% 325 $880.51
87046 <1% 846 $878.16
82652 <1% 228 $870.64
87906 <1% 13 $858.67
73030 <1% 65 $857.34
87521 Neg quan hep c or qual rna <1% 61 $851.68
85018 <1% 2,169 $842.81
82274 <1% 183 $832.42
73564 <1% 41 $811.95
82565 <1% 796 $794.00
86747 <1% 74 $791.59
82952 <1% 1,014 $766.39
85660 <1% 739 $765.01
86677 <1% 133 $754.48
G0008 Administration of influenza virus vaccine <1% 173 $753.19
82378 <1% 147 $744.99
86708 <1% 300 $729.92
87493 <1% 43 $728.64
73502 <1% 46 $719.58
86255 <1% 274 $673.77
85045 <1% 861 $629.72
86618 <1% 76 $626.96
84154 <1% 137 $602.96
87255 <1% 69 $573.03
80164 <1% 236 $566.77
87210 <1% 471 $560.66
84445 <1% 46 $547.43
U0001 Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel <1% 27 $538.31
88185 <1% 341 $519.16
87625 <1% 67 $464.55
82977 <1% 425 $458.62
86148 <1% 146 $455.24
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 36 $433.99
86308 <1% 413 $403.84
82248 <1% 250 $392.84
95012 <1% 77 $365.64
85014 <1% 979 $364.31
86593 <1% 388 $348.78
87184 <1% 150 $329.36
82672 <1% 42 $324.64
81025 <1% 499 $306.75
84446 <1% 25 $293.48
84238 <1% 38 $291.80
72100 <1% 25 $288.98
82575 <1% 82 $273.33
80051 <1% 263 $266.58
84520 <1% 411 $255.13
85732 <1% 111 $245.00
84590 <1% 25 $240.35
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 22 $238.42
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 147 $238.08
85613 <1% 107 $223.42
82024 <1% 47 $223.14
81003 <1% 322 $214.60
83519 <1% 49 $208.29
86617 <1% 13 $201.30
86777 <1% 100 $198.27
71045 Radiologic examination, chest; single view <1% 29 $192.78
82164 <1% 61 $189.75
83498 <1% 75 $184.14
88312 <1% 59 $181.57
86645 <1% 42 $165.14
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 15 $165.00
86021 <1% 111 $152.84
87040 <1% 22 $145.28
86644 <1% 42 $143.47
86705 <1% 33 $135.88
69209 <1% 19 $122.45
82310 <1% 120 $121.73
86870 <1% 20 $114.40
82040 <1% 67 $105.80
83921 <1% 12 $105.57
82465 <1% 106 $104.89
86256 <1% 16 $104.88
82390 <1% 47 $99.51
82272 <1% 104 $95.40
84432 <1% 16 $90.50
82397 <1% 24 $81.18
80177 <1% 22 $79.70
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 80 $79.36
85379 <1% 40 $77.41
82955 <1% 37 $77.31
86664 <1% 24 $76.45
81050 <1% 88 $70.72
86880 <1% 32 $66.18
82247 <1% 48 $65.18
82166 <1% 16 $63.39
84482 <1% 16 $63.04
83993 <1% 15 $60.78
80178 <1% 33 $57.69
82679 <1% 31 $54.41
82962 <1% 222 $53.90
84630 <1% 15 $44.26
80183 <1% 12 $38.83
84425 <1% 12 $38.48
83721 <1% 17 $36.74
81596 <1% 13 $34.64
84134 <1% 15 $32.60
82103 <1% 14 $26.34
84270 <1% 12 $23.91
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 25 $22.20
82140 <1% 12 $17.71
84155 <1% 13 $8.95
82270 <1% 12 $7.34
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units <1% 49 $0.93
90460 Immunization administration through 18 years of age via any route, first or only component 0% 15 $0.00
J7512 Prednisone, immediate release or delayed release, oral, 1 mg 0% 13 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHEDLEY, KENNETH (PRESIDENT)
Same official

Other billing entities under HEDLEY, KENNETH

Full network →
ProviderLocationPaid
Central Dupage Hospital AssociationWinfield, IL$30K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.